Literature DB >> 11170106

Investigation of suspected deficient Fas-mediated apoptosis in a father and son.

M G Hanlon1, M L Gacis, A M Kakakios, H Kilham.   

Abstract

BACKGROUND: A 2-year-old boy presented with symptoms consistent with a diagnosis of autoimmune lymphoproliferative syndrome (ALPS). His father had been splenectomized at age 12 with similar symptoms. ALPS is a rare hereditary syndrome that may result from a functional defect in Fas-mediated apoptosis.
METHODS: Peripheral blood lymphocytes (PBL) and splenic lymphocytes from the patient and PBL from his father and a normal control were analyzed for surface Fas expression. They were then stimulated with an anti-Fas monoclonal antibody (DX2). Apoptosis was assayed by flow cytometry at 0, 20, 28, and 34 h.
RESULTS: There was no significant difference in expression of Fas (CD95) in the PBL of the patient, his father, or the normal control, or the splenic lymphocytes. Compared with the normal control, the PBL of the patient and his father failed to progress to apoptosis. They also contained a markedly elevated proportion of CD3+CD4-CD8- "double-negative" cells.
CONCLUSIONS: PBL from both the patient and his father expressed CD95, but failed to proceed to apoptosis after stimulation, suggesting a functional defect. These results and the clinical presentation are consistent with published descriptions of ALPS. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170106

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  2 in total

Review 1.  Autoimmune lymphoproliferative syndrome: etiology, diagnosis, and management.

Authors:  Jutte van der Werff ten Bosch
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

2.  Effects of apigenin on the expression levels of B-cell lymphoma-2, Fas and Fas ligand in renal ischemia-reperfusion injury in rats.

Authors:  Yang Liu; Xiuheng Liu; Lei Wang; Yang Du; Zhiyuan Chen; Hui Chen; Jia Guo; Xiaodong Weng; Xiao Wang; Ming Wang; Zhishun Wang
Journal:  Exp Ther Med       Date:  2017-10-02       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.